Chell Jeffrey W. Form 3 May 01, 2018

### FORM 3

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

Chell Jeffrey W.

C/O ACTINIUM

PHARMACEUTICALS, INC.. 275 MADISON

AVENUE, 7TH FLOOR

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

04/27/2018

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Actinium Pharmaceuticals, Inc. [ATNM]

4. Relationship of Reporting

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Form filed by More than One

Person(s) to Issuer

(Check all applicable)

10% Owner \_X\_ Director Officer Other (give title below) (specify below)

NEW YORK, NYÂ 10016

(Street)

(State)

Reporting Person Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(City)

(Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Form:

4. Nature of Indirect Beneficial Ownership

Ownership (Instr. 5)

Person

or Indirect (I) (Instr. 5)

Direct (D)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of Price of Derivative

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Derivative Security:

1

#### Edgar Filing: Chell Jeffrey W. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Options to purchase common stock	04/27/2018(1)	04/27/2028	Common Stock	75,000	\$ 0.35	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
<b>Fg</b>	Director	10% Owner	Officer	Other	
Chell Jeffrey W.					
C/O ACTINIUM PHARMACEUTICALS, INC.	λv	Â	Â	Â	
275 MADISON AVENUE, 7TH FLOOR	АЛ	А	A	A	
NEW YORK, NY 10016					

# **Signatures**

/s/ Jeffrey W.
Chell

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Options granted on April 27, 2018 to purchase an aggregate of 75,000 shares of common stock. A total of 28% of the options will vest (1) one year from the grant date, and the remaining 72% shall vest in equal increments of 2% per month of the initial option grant over the following three year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2